Safety and efficacy review of inhaled loxapine for treatment of agitation.
Safety and efficacy review of inhaled loxapine for treatment of agitation.
复制标题
DOI：
10.3371/csrp.cuwa.032513
复制
发表时间：
2013-04-01
影响因子：
--
通讯作者：
Walsh, Patrick
中科院分区：
文献类型：
--
作者：
Currier, Glenn;Walsh, Patrick
躁动在急性精神分裂症和双相情感障碍患者中很常见，快速有效地治疗急性躁动是一个重要的临床目标。洛沙平是美国第一代口服抗精神病药物，已有30多年的历史。2012年12月，美国食品药品监督管理局（FDA）批准了一种吸入型汽化洛沙平，用于治疗患有精神分裂症或双相情感障碍的躁动成年人。在这篇综述中，我们检查了现有的文献来描述吸入洛沙平在健康患者和肺损害患者中的有效性和安全性。目前的证据基础的局限性，以预测“现实世界”患者的疗效描述，和必要的保障措施，适当地使用精神病学急性护理设置进行了讨论。
Agitation is common in patients with acute schizophrenia and bipolar disorder, and rapid and effective treatment of acute agitation is an important clinical goal. Loxapine is a first-generation antipsychotic medication available in the United States in oral form for more than three decades. In December 2012, an inhaled version of vaporized loxapine was approved by the U.S. FDA for the treatment of agitated adults in the context of schizophrenia or bipolar disorder. In this review, we examine available literature to describe efficacy and safety of inhaled loxapine in healthy patients and in those with pulmonary compromise. Limitations of the current evidence base to predict efficacy in "real world" patients are described, and safeguards necessary for appropriate use in psychiatric acute care settings are discussed.